ST2 as a Marker for Risk of Therapy-Resistant Graft-versus-Host Disease and Death
Mark T. Vander Lugt(University of Michigan–Ann Arbor), Sophie Paczesny(MUSC Hollings Cancer Center), Qing Zhang(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), James L.M. Ferrara(Tisch Hospital), Andrew C. Harris(Primary Children's Hospital), Vincent T. Ho(Dana-Farber Cancer Institute), Samir Hanash(The University of Texas MD Anderson Cancer Center), John E. Levine(Icahn School of Medicine at Mount Sinai), Joseph H. Antin(Dana-Farber Cancer Institute), Sung Won Choi(University of Michigan), Chee‐Hong Wong(The University of Texas MD Anderson Cancer Center), Daniel R. Couriel(The University of Texas MD Anderson Cancer Center), Pavan Reddy(Wichita State University), Hong Wang(Zhejiang University of Technology), Thomas Braun(University of Michigan), Aurélie Gomez(University of Michigan), Alice Chin(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Jerome Ritz(Dana-Farber Cancer Institute)
Cited by 403
Related Papers
Detection and localization of surgically resectable cancers with a multi-analyte blood test
|Science|2018|2.8k
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
|Nature|2018|1.5k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
|New England Journal of Medicine|2011|1.1k